Pantoprazole
Uses
Pantoprazole, a proton pump inhibitor (PPI), is used to manage various acid-related gastrointestinal conditions, including:
- Gastroesophageal Reflux Disease (GERD): Symptomatic relief and healing of erosive esophagitis.
- Erosive Esophagitis: Associated with GERD or other acid-peptic disorders.
- Zollinger-Ellison Syndrome: Management of hypersecretory conditions.
- Peptic Ulcer Disease: Adjunct to eradication therapy for Helicobacter pylori or prevention of NSAID-induced ulcers.
Dosage and Administration
Oral Administration
- Children: 1–2 mg/kg once daily (maximum 40 mg/day).
- Adults: 40 mg once daily; severe cases may require 80 mg/day.
Intravenous Administration
- Children: 0.5–1 mg/kg once daily (maximum 40 mg/day).
- Adults: 40 mg once daily; up to 80 mg/day if clinically indicated.
Infusion Protocol
- Initial Bolus: 2 mg/kg IV over 15 minutes.
- Continuous Infusion: 0.2 mg/kg/hour for severe conditions requiring sustained acid suppression.
Presentation
- Tablets: 20 mg, 40 mg.
- Injection: 40 mg/vial (for IV use).
Pharmacokinetics
-
Absorption:
- Oral bioavailability ~77%, unaffected by food.
- Peak plasma concentration achieved within 2–2.5 hours.
-
Distribution:
- Plasma protein binding ~98%.
-
Metabolism:
- Extensively metabolized in the liver via CYP2C19 and CYP3A4.
- Metabolites are inactive.
-
Excretion:
- Primarily via urine (~80%) and feces (~20%).
-
Plasma Half-Life:
- 1–1.5 hours; however, effects persist due to prolonged binding to the H+/K+ ATPase pump.
Pharmacodynamics
Pantoprazole works by inhibiting the proton pump (H+/K+ ATPase) in the gastric parietal cells, thereby:
- Reducing gastric acid secretion, leading to increased gastric pH.
- Suppressing both basal and stimulated acid production regardless of stimulus (e.g., histamine, gastrin).
- Providing prolonged acid suppression even after plasma levels decline.
Drug Interactions
- Drugs Requiring Gastric Acidity for Absorption:
- Reduced absorption of drugs like ketoconazole, itraconazole, and iron salts.
- Clopidogrel:
- May reduce the antiplatelet activity of clopidogrel by inhibiting CYP2C19.
- Methotrexate:
- High-dose methotrexate may have delayed clearance due to pantoprazole.
- Warfarin:
- Increased INR and bleeding risk when co-administered.
Precautions and Special Considerations
- Long-Term Use Risks:
- May lead to vitamin B12 deficiency, hypomagnesemia, and increased risk of osteoporotic fractures.
- Hepatic Impairment:
- Dose adjustment required in severe hepatic dysfunction.
- Hypomagnesemia:
- Monitor for symptoms like seizures, muscle cramps, and arrhythmias in long-term therapy.
- Clostridioides difficile Infection:
- Chronic use may increase the risk of C. difficile-associated diarrhea.
Pregnancy and Lactation
- Pregnancy Category B (FDA):
- No evidence of fetal harm in animal studies; however, limited human data. Use only if clearly needed.
- Lactation:
- Pantoprazole is excreted in breast milk. Use with caution in breastfeeding mothers.
Side Effects
Common:
- Headache, diarrhea, nausea, flatulence, and abdominal pain.
Serious:
- Hypomagnesemia, vitamin B12 deficiency, bone fractures, and interstitial nephritis.
Recent Updates and Guidelines
-
American College of Gastroenterology (2022):
- Pantoprazole remains a first-line therapy for GERD and erosive esophagitis.
-
FDA Safety Communication (2021):
- Emphasis on monitoring for hypomagnesemia during prolonged use.
-
Management of Zollinger-Ellison Syndrome (2023):
- High-dose pantoprazole (80–160 mg/day) recommended for effective acid suppression.
References
- Lexicomp Online, Pantoprazole: Drug Information, 2023.
- UpToDate, Pantoprazole: Patient Drug Information, 2023.
- Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13th Edition, McGraw-Hill Education, 2017.
- FDA Drug Safety Communications, Pantoprazole Monitoring Guidelines, 2021.
- American College of Gastroenterology Guidelines for GERD and PUD Management, 2022.
You should also know about
No comments:
Post a Comment